Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review
Authors' conclusion
Our results showed that abatacept and tocilizumab were more frequently used in patients with localized scleroderma, while rituximab and tocilizumab were the predominantly used biologics in patients with systemic sclerosis. The improvement rate with these biologics were quite high with acceptable safety profile.
Study context
- Population
- Pediatric patients with localized scleroderma and SSc treated with biologic drugs29 articles
- Participants
- 58 vs 29
- Comparison
- Localized scleroderma vs Systemic sclerosis
- Localized scleroderman = 58
- Systemic sclerosisn = 29
- Outcome
- Biologic use and improvement rates
Methodological detailsMEDLINE and Scopus search
- MEDLINE and Scopus search
Main finding
As reported in the abstract
- Localized scleroderma: abatacept use
- 55.2 %
- Localized scleroderma: tocilizumab use
- 48.3 %
- Localized scleroderma: abatacept and tocilizumab used mainly for resistant/progressive skin disease (respectively)
- 58.5 % and 68.8 %
- Localized scleroderma: improvement rate with abatacept
- 92.9 %
- Localized scleroderma: improvement rate with tocilizumab
- 77.4 %
- SSc: RTX use
- 51.7 %
- SSc: tocilizumab use
- 44.8 %
- SSc: RTX used for cardiac involvement
- 45.5 %
- SSc: tocilizumab used for pulmonary involvement
- 50 %
- SSc: improvement rate with RTX
- 72.7 %
- SSc: improvement rate with tocilizumab
- 94.1 %
Safety
Adverse events
Original publication
Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review. Semin Arthritis Rheum. Published 29 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →